LL-37
Animal / preclinicalAlso known as: Cathelicidin fragment
Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A human antimicrobial peptide studied for immune and wound-healing roles. It is a double-edged molecule in research and unproven as an injectable product.
Mechanism
Host-defence peptide with antimicrobial and immunomodulatory activity; context-dependent effects.
Evidence
Thin for product claims; complex biology and no human efficacy trials for supplemental use.
Community-reported information
Community reports vary. Anecdotal and unvalidated; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Short.
Storage
Refrigerate solutions.
Commonly reported side effects
- Not well characterised in humans
- Injection-site reactions reported anecdotally
Legal status by region
- USNot FDA-approved for human use.
Legal status changes over time; verify locally before relying on this.